Brightening Cream and Lasers in Post-sclerotherapy Hyperpigmentation

Not Applicable

Completed

• Conditions: Hyperpigmentation; Varicosis
• Interventions: Drug: Triple cream

• Registration Number: NCT05165524
• Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Brief Summary

The treatment of leg veins and varicosis with sclerotherapy is one of the most frequently performed medical intervention in the western world. The most common local side effects of this treatment are hyperpigmentations caused by hemosiderin deposition in the skin as well as post inflammatory hyperpigmentation.

Although skin hyperpigmentation after sclerotherapy is a common over several months up to years lasting side-effect with a strong aesthetic impact, scanty data exist about treatment options.

Quality-Switched (QS) lasers are efficient in the removal of exogenous and endogenous pigments, such as tattoos as well as epidermal and dermal melanin deposits. The laser light is absorbed by pigment particles, leading to a fragmentation of these particles by a photothermal and photoacoustic effect. Smaller particles can be then phagocyted by macrophages, and transported via the lymphatic system into the lymph nodes. Furthermore, the positive effect of QS lasers in the management of cutaneous siderosis in stasis dermatitis and after sclerotherapy has been described in several cases.

Triple cream including hydroquinone, tretinoin and a topical corticosteroid (eg dexamethasone), is the first line therapy in the treatment of post inflammatory hyperpigmentation.

This randomized controlled study aims to evaluate the efficiency of two well-known depigmentation methods (QS laser and triple cream) for treatment of post sclerotherapy hyperpigmentation, compared with a control group performing no treatment.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-12-07
• Study First Submitted QC: 2021-12-20
• Study First Posted: 2021-12-21
• Study Start: 2022-03-03
• Primary Completion: 2025-01-14
• Study Completion: 2025-01-14
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-18
• Last Update Posted: 2025-03-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

• Fitzpatrick skin type I-IV
• Presence of at least 1 postinflammatory hyperpigmentation after sclerotherapy

Exclusion Criteria

• History of adverse events related to short-pulsed laser therapy
• Pregnant or breast-feeding women
• Intention to become pregnant during the course of the study
• History of intolerance or allergic reaction to triple cream or one of its ingredients
• Prior treatment with parenteral gold therapy
• Inability to understand the study content

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cream	Triple cream	-

Primary Outcome Measures

Name	Time	Method
Equivalence of laser and cream in reducing post-sclerotherapy hyperpigmentation as assessed by SHI	16 weeks	Equivalence of laser and cream groups in reducing post-sclerotherapy hyperpigmentation as assessed by Skin Hyperpigmentation Index (SHI), ranging from 1 to 4, with higher score indicating a worst hyperpigmentation.

Secondary Outcome Measures

Name	Time	Method
Efficacy of laser and cream in reducing post-sclerotherapy hyperpigmentation compared to control group as assessed by SHI	4, 8, 12, 16 weeks	Any reduction of post-sclerotherapy hyperpigmentation in laser and cream compared to control group as assessed by Skin Hyperpigmentation Index (SHI), ranging from 1 to 4, with higher score indicating a worst hyperpigmentation.
Efficacy of laser and cream in reducing post-sclerotherapy hyperpigmentation compared to control group as assessed by PGA	4, 8, 12, 16 weeks	Any reduction of post-sclerotherapy hyperpigmentation in laser and cream compared to control group as assessed by 6-point Physician Global Assessment (PGA), based on before-after pictures of lesions assessment, ranging from 1 to 6, with higher scores indicating a better outcome.
Patient's satisfaction related to laser and cream in reducing post-sclerotherapy hyperpigmentation compared to control group	16 weeks	Any difference of patient's satisfaction between laser and cream compared to control group as assessed by a 9-point anchored visual analogue scale (VAS), ranging from -4 to +4, with negative scores indicating a worsening of condition, with 0 indicating no difference and with positive scores indicating an improvement.

Trial Locations

Locations (1)

Department of dermatology, University Hospital Inselspital, Bern; 🇨🇭 Bern, Switzerland